Investors in Agenus Inc. Can Join Class Action Lawsuit
Investors in Agenus Inc. are now being informed about their chance to participate in a class action lawsuit against the company and certain officers. This lawsuit stems from allegations of possible violations of federal securities laws, with the goal of safeguarding the interests of shareholders who bought securities during the designated class period.
A Closer Look at the Class Action Lawsuit
This class action aims to recover damages for anyone who purchased Agenus securities between early 2023 and mid-2024. The allegations suggest that the company made material false statements about its initiatives, particularly regarding the combined therapy of botensilimab and balstilimab.
Allegations Directed at Agenus
The complaint claims that, during this timeframe, the defendants allegedly shared misleading information concerning the effectiveness of their drug therapies. It states that the reported clinical results were exaggerated and that there was a notable discrepancy between the company's assertions and the actual effectiveness of their treatments. This raised significant questions about the reliability of the company’s public statements.
Steps for Affected Investors
Investors who believe they have incurred losses during the defined class period are encouraged to take action. The court has set a deadline for those affected to express their interest in becoming lead plaintiff by the end of 2024. It's important to note that you don’t have to take on the role of lead plaintiff to be eligible for any recovery. This represents a significant chance for investors to seek the justice they deserve.
Examining the Complaint
A class action complaint has already been filed, and individuals interested can review it for more details about the allegations. Additionally, there’s easy access for those wanting to get in touch with legal representatives to discuss their potential claims and learn more about the lawsuit.
No Cost for Investors
Importantly, participating in the class action comes at no upfront cost to investors. The law firm that represents the plaintiffs works on a contingency fee basis, meaning there are no initial costs. Expenses and attorney fees are only charged if the case is won, providing peace of mind for those considering participating.
Selecting the Right Legal Team
Bronstein, Gewirtz & Grossman, LLC is managing the case and is well-regarded for their work with investors in similar legal disputes. Their history includes successfully recovering substantial sums for those affected by securities fraud, demonstrating their commitment to defending shareholder rights.
A Dedicated Team for Collective Fight
The firm underscores the vital role of investor representation in class actions, stressing that their experience and dedication can greatly influence the case’s outcome. Having a skilled legal team can be crucial for individuals looking to recover losses from their investments in Agenus Inc.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit focuses on alleged false and misleading statements made by Agenus regarding their drug therapies, seeking to recover damages for investors who were affected.
Who can join the class action?
Anyone who purchased Agenus securities between January 2023 and July 2024 is eligible to potentially join the class action lawsuit.
What should interested investors do next?
Investors should reach out to the law firm representing the class action to express their interest in participating and to obtain further information.
Are there any costs associated with participating in the class action?
No, investors will not face any costs unless the case is successful, as legal fees are charged on a contingency basis.
Why is Bronstein, Gewirtz & Grossman, LLC a good choice?
This firm is known for its successful representation of investors in securities fraud cases, boasting a record of securing significant recoveries for their clients.
